uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
177Lu-DOTATATE peptide receptor radionuclide therapy: dose response in small intestinal neuroendocrine tumors.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Radiology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Radiology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Radiology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Radiology.
Show others and affiliations
2019 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194Article in journal (Refereed) Epub ahead of print
Abstract [en]

INTRODUCTION: Peptide receptor radionuclide therapy (PRRT) has during the last few years become frequently used in patients with progressive, disseminating well differentiated neuroendocrine tumors (NETs).

OBJECTIVE: To study whether the absorbed dose (AD) in small intestinal NET (SI-NET) metastases from PRRT with 177Lu-DOTATATE is related to tumor shrinkage.

MATERIALS AND METHODS: Dosimetry for one tumor was performed in each of 25 SI-NET patients based on sequential SPECT/CT at 1, 4 and 7 days after 177Lu-DOTATATE infusion. The SPECT data were corrected for the partial volume effect based on previous phantom measurements, and the unit density sphere model from OLINDA was used for absorbed dose calculations. Morphological therapy response was assessed by CT/MRI regarding tumor diameter, tumor volume, total liver tumor volume, liver volume and overall tumor response according to RECIST 1.1. Plasma chromogranin A and urinary 5-hydroxy-indole-acetic-acid were measured during PRRT and follow-up to assess biochemical response.

RESULTS: At the time of best response (BR) for tumor diameter and volume shrinkage the median absorbed dose was 128.6 Gy (range 28.4-326.9), and 140 Gy (range 50.9- 487.4), respectively. All metrics regarding tumor shrinkage and biochemical response were unrelated to the absorbed dose. A correlation was, however, found between the administered activity and the tumor volume shrinkage (p=0.01) and between the administered activity and RECIST 1.1 response (p=0.01).

CONCLUSIONS: It was not possible to demonstrate a tumor dose-response relationship in SI-NET metastases, with the applied dosimetry method, contrary to what was previously shown for pancreatic NETs.

Place, publisher, year, edition, pages
2019.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-397541DOI: 10.1159/000504001PubMedID: 31597134OAI: oai:DiVA.org:uu-397541DiVA, id: diva2:1371988
Available from: 2019-11-21 Created: 2019-11-21 Last updated: 2019-11-21

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Jahn, UlrikaIlan, EzgiSandström, MattiasGarske-Román, UlrikeLubberink, MarkSundin, Anders
By organisation
Radiology
In the same journal
Neuroendocrinology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 18 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf